anastrazole

Phase 3Small molecule

AstraZeneca

anastrazole is one of 55 small molecule programs targeting Inguinal hernia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inguinal HerniaRecruiting

SteroidUnknown status

Breast CancerCompleted

Inguinal HerniaPhase 1

Recruiting

SteroidPreclinical

Unknown status

Breast CancerPhase 3

Completed

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

anastrazole

AstraZeneca

Phase 3

6 2

Adenocard

Astellas

Preclinical

2 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Duragesic

CCephalon

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Rilvegostomig

1 7

Ablavar

LLantheus Medical Imaging

Preclinical

2 8

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Lapatinib Plus Capecitabine

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Inguinal Hernia

NCT07604272

Q3 2030

Phase 2Recruiting

Breast Cancer

NCT06953882

Q4 2033

Phase 2Recruiting

Ductal Carcinoma in Situ

NCT06075953

Clinical

Trials by Indication[1]

Breast Cancer6 trials

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Recruiting·YYale University·Phase 2·NCT06953882·140 enrolled

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00605267·197 enrolled

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT00022672·208 enrolled

Show 3 more trials

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00921115·42 enrolled

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Withdrawn·MMedical College of Wisconsin·Phase 1·NCT04316169

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00259090·120 enrolled

Growth1 trial

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Completed·MMayo Clinic·Phase 1·NCT00309855·80 enrolled

Weight loss1 trial

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

Completed·—·Phase 4·NCT02959853·23 enrolled

Neoadjuvant1 trial

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00255463·185 enrolled

Endometriosis1 trial

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Completed·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 4·NCT01769781·70 enrolled

3 more indications

Steroid1 trial

Metabolic Effects of Steroids in Obese Men

Unknown status·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00983554·57 enrolled

Inguinal hernia1 trial

Reversing InGuinal Hernia Trial (RIGHT Trial): The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

Recruiting·NNorthwestern University·Phase 1·NCT07604272·30 enrolled

Ductal Carcinoma in Situ1 trial

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT06075953·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for anastrazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anastrazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anastrazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

anastrazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2030

Q4 2033

Trials by Indication[1]

Breast Cancer6 trials

Growth1 trial

Weight loss1 trial

Neoadjuvant1 trial

Endometriosis1 trial

Steroid1 trial

Inguinal hernia1 trial

Ductal Carcinoma in Situ1 trial

References

Drug Info

Quick Facts

Related News